1 / 43

Precision Medicine Market 2018-2028

The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028.

bisreports
Télécharger la présentation

Precision Medicine Market 2018-2028

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Precision Medicine Market Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping, and Competitive Landscape - Analysis and Forecast: 2018-2028 January 2019

  2. Global Precision Medicine Market BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2019 BIS Research All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by, or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research 2

  3. Global Precision Medicine Market Click Here to Nominate Yourself or Someone You Know Now All rights reserved at BIS Research 3

  4. Global Precision Medicine Market Preface Preface In recent times, the increased prevalence of several chronic diseases, including cancer, diabetes, and cardiovascular diseases, is considered to be one of the leading causes of mortality. With the increasing life span and life expectancy, the geriatric population is growing at a fast pace and is expected to witness a surge in the future. Consequently, the surge in demand for better treatment outcomes is leading to the ascending need for early diagnosis and tailored medication. The growth of the personalized medicine market over the last few years (2010-2017) has been colossal. Novel technologies, including next-generation sequencing and biomarker assays, are being rapidly approved by regulatory bodies including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), thus expanding the arsenal of tools accessible to support the development and adoption of novel vaccines over “one-size-fits-all” therapies and treatment. In order to facilitate the development of targeted vaccines, the number of commercialized biologics and delivery techniques has increased, especially in the case of infectious diseases and cancer. The newly developed techniques and drugs for target diseases not only facilitate parallel development of targeted drugs but also provide essential information for patient classification for enabling effective genome study and optimizing corresponding treatment. Moreover, targeted therapies help healthcare professionals to treat patients with great efficacy and less time duration. Thus, novel vaccines eliminate the uncertainty of trial-and-error method of medications and reduce unnecessary healthcare expenditure. The following report “Global Precision Medicine Market” explains the importance of the personalized medicines, the individualized therapies, the technological advancements involved with the development of different technologies in the precision medicine ecosystem, the factor affecting growth of the market, and the challenges faced by the key players in the market. The report also covers the competitive landscape of the market, industry attractiveness, growth potential, and market dynamics. The intensifying cancer incidences, rising geriatric population, increasing health consciousness, and expanding adoption of vaccine approach over “one-drug-for-all-patients” treatment method in developed as well as developing economies are expected to be the major factors for the growth of the market. The report has been segmented into three sections namely, ecosystem, application, and region. Each segment is further sub-segmented and provides data for the market revenue from 2017 to 2028. All rights reserved at BIS Research 4

  5. Global Precision Medicine Market Key questions answered in the report:  What are the major market drivers, challenges, and opportunities in the global precision medicine market?  What are the underlying structures resulting in the emerging trends within the precision medicine market?  What was the market value of the leading segments and sub-segments of the global precision medicine market in 2017?  How will each segment of the global precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?  What are the influencing factors that may affect the market share of the key players?  How will the industry evolve during the forecast period 2018- 2028?  What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?  What are the key ecosystem type in the global precision medicine market? What are the major benefits of each type?  How has the market been segmented on the basis of application type? Which application type is dominating the global precision medicine market and what is the reason behind such domination?  Which ecosystem type is having the most promising growth and in which application type?  What is the market share of each of the companies in the global precision medicine market and what are their contributions?  What is the scope of each type of ecosystem in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?  What is the growth potential of precision medicine in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? BIS Healthcare January 2019 All rights reserved at BIS Research 5

  6. Global Precision Medicine Market T Table of able of C Contents ontents Executive Summary ........................................................................................................ 40 1. Market Overview ................................................................................................... 75 1.1 1.2 Introduction ..................................................................................................... 75 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine ........................................................................................................... 77 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy ......................................................................... 78 Initiatives and Programs................................................................................. 82 Assumptions and Limitations for Market Size Calculations ....................... 86 Precision Medicine: Enabling Technologies ................................................ 86 1.6.1 Innovators ............................................................................................. 87 1.6.1.1 3D DNA Printing ..................................................................................... 87 1.6.1.1.1 Introduction ....................................................................................... 87 1.6.1.1.2 Role of 3D DNA Printing ................................................................... 87 1.6.1.2 RNA-Seq ................................................................................................ 88 1.6.1.2.1 Introduction ....................................................................................... 88 1.6.1.2.2 Role of RNA-Seq in Precision Medicine ............................................ 88 1.6.1.2.3 Key Players ....................................................................................... 88 1.6.1.3 4D Molecular Imaging ............................................................................. 89 1.6.1.3.1 Introduction ....................................................................................... 89 1.6.1.3.2 Role of 4D Molecular Imaging in Precision Medicine ........................ 89 1.6.1.3.3 Key Players ....................................................................................... 89 1.6.2 Early Adopters ...................................................................................... 89 1.6.2.1 CRISPR .................................................................................................. 89 1.6.2.1.1 Introduction ....................................................................................... 89 1.6.2.1.2 Role of CRISPR in Precision Medicine ............................................. 90 1.6.2.1.3 Key Players ....................................................................................... 91 1.6.2.2 Blockchain .............................................................................................. 91 1.6.2.2.1 Introduction ....................................................................................... 91 1.6.2.2.2 Role of Blockchain in Precision Medicine .......................................... 91 1.6.2.2.3 Key Players ....................................................................................... 92 1.3 1.4 1.5 1.6 All rights reserved at BIS Research 6

  7. Global Precision Medicine Market 1.6.2.3 1.6.2.3.1 1.6.2.3.2 1.6.2.3.3 1.6.3 1.6.3.1 1.6.3.1.1 1.6.3.1.2 1.6.3.1.3 1.6.3.2 1.6.3.2.1 1.6.3.2.2 1.6.3.2.3 1.6.3.3 1.6.3.3.1 1.6.3.3.2 1.6.3.3.3 1.6.3.4 1.6.3.4.1 1.6.3.4.2 1.6.3.4.3 1.6.3.5 1.6.3.5.1 1.6.3.5.2 1.6.3.5.3 1.6.3.6 1.6.3.6.1 1.6.3.6.2 1.6.3.6.3 1.6.4 1.6.4.1 1.6.4.1.1 1.6.4.1.2 Imaging Informatics ................................................................................ 92 Introduction ....................................................................................... 92 Role of Imaging Informatics in Precision Medicine ............................ 92 Key Players ....................................................................................... 93 Early Majority ........................................................................................ 93 Artificial Intelligence (AI) ......................................................................... 93 Introduction ....................................................................................... 93 Role of Artificial Intelligence in Precision Medicine ........................... 93 Key Players ....................................................................................... 93 Circulating free DNA (cfDNA) ................................................................. 94 Introduction ....................................................................................... 94 Role of cfDNA in Precision Medicine ................................................. 94 Key Players ....................................................................................... 94 Big Data .................................................................................................. 95 Introduction ....................................................................................... 95 Role of Big Data in Precision Medicine ............................................. 95 Key Players ....................................................................................... 96 Next-Generation Sequencing (NGS) ...................................................... 96 Introduction ....................................................................................... 96 Role of NGS in Precision Medicine ................................................... 97 Key Players ....................................................................................... 97 Health Informatics................................................................................... 97 Introduction ....................................................................................... 97 Role of Health informatics in Precision Medicine .............................. 98 Key players ....................................................................................... 99 Bioinformatics ......................................................................................... 99 Introduction ....................................................................................... 99 Role of Bioinformatics in Precision Medicine .................................... 99 Key Players ....................................................................................... 99 Late Majority ....................................................................................... 100 Polymerase Chain Reactions (PCR) .................................................... 100 Introduction ..................................................................................... 100 Role of PCR in Precision Medicine ................................................. 100 All rights reserved at BIS Research 7

  8. Global Precision Medicine Market 1.6.4.1.3 1.6.4.2 1.6.4.2.1 1.6.4.2.2 Key players ..................................................................................... 100 Microarray ............................................................................................ 100 Role of Microarray in Precision Medicine ........................................ 101 Key Players ..................................................................................... 101 2. Market Dynamics ................................................................................................ 102 2.1 2.2 Impact Analysis ............................................................................................. 103 Market Drivers ............................................................................................... 104 2.2.1 Advancement of Sequencing Technologies .................................... 104 2.2.2 Rising Prevalence of Chronic Diseases ........................................... 107 2.2.3 Growing Demand for Preventive Care .............................................. 110 2.2.4 Shifting the Significance in Medicine, from Reaction to Prevention ........................................................................................... 111 2.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test ................................................................... 111 2.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe ................................................................................................... 112 2.3 Market Restraints .......................................................................................... 112 2.3.1 Unified Framework for Data Integration ........................................... 112 2.3.2 Limited Knowledge About Precision Medicine Application ........... 113 2.3.3 Lack of Robust Reimbursement Landscape .................................... 114 2.3.4 Regulatory Hurdles ............................................................................ 114 2.4 Market Opportunities .................................................................................... 117 2.4.1 Targeted Gene Therapy ..................................................................... 117 2.4.2 Expansion into the Emerging Markets ............................................. 118 2.4.3 Collaboration and Partnerships Across Value Chain Would Accelerate the Market Entry .............................................................. 119 3. Competitive Insights .......................................................................................... 121 3.1 Key Developments and Strategies .............................................................. 122 3.1.1 Joint Ventures, Partnerships, Agreements, and Collaborations .... 123 3.1.2 Product launches, Enhancements, and Upgradation ...................... 124 3.1.3 Product Approvals ............................................................................. 126 3.1.4 Merger and Acquisitions .................................................................... 127 3.1.5 Business Expansion .......................................................................... 128 All rights reserved at BIS Research 8

  9. Global Precision Medicine Market Other Developments .......................................................................... 129 Market Share Analysis .................................................................................. 130 3.2.1 Market Share Analysis by Applied Sciences, 2017.......................... 131 3.2.2 Market Share Analysis by Precision Diagnostics, 2017 .................. 133 3.2.3 Market Share Analysis by Precision Therapeutics, 2017 ................ 135 3.2.4 Market Share Analysis by Digital Health and IT, 2017 ..................... 136 3.3 Industry Attractiveness ................................................................................ 137 3.3.1 Definition of Suppliers and Buyers in the Precision Medicine Market .................................................................................................. 138 3.3.2 Bargaining Power of Suppliers ......................................................... 139 3.3.3 Bargaining Power of Buyers ............................................................. 140 3.3.4 Threat of New Entrants ...................................................................... 141 3.3.5 Threat of Substitute Products ........................................................... 142 3.3.6 Intensity of Competitive Rivalry ........................................................ 144 3.4 Supply Chain Analysis.................................................................................. 145 3.1.6 3.2 4. Industry Insights ................................................................................................. 147 4.1 4.2 4.3 Patent Analysis ............................................................................................. 147 Legal Requirements and Regulations ......................................................... 148 Pipeline Analysis ........................................................................................... 150 5. Global Precision Medicine Market (by Ecosystem) ......................................... 157 5.1 5.2 Overview ........................................................................................................ 157 Applied Sciences .......................................................................................... 160 5.2.1 Genomics ............................................................................................ 162 5.2.1.1 Polymerase Chain Reaction (PCR) ...................................................... 165 5.2.1.2 Precision Medicine Next-Generation Sequencing (PM NGS) ............... 168 5.2.1.3 Genome Editing .................................................................................... 174 5.2.1.4 Other Technologies .............................................................................. 178 5.2.2 Pharmacogenomics ........................................................................... 179 5.2.3 Other Applied Sciences ..................................................................... 188 5.3 Precision Diagnostics ................................................................................... 189 5.3.1 Molecular Diagnostics (MDx) ............................................................ 192 5.3.1.1 Non-invasive Prenatal Testing (NIPT) .................................................. 196 All rights reserved at BIS Research 9

  10. Global Precision Medicine Market 5.3.1.2 5.3.1.3 5.3.1.4 5.3.2 5.3.2.1 5.3.2.2 5.4 5.4.1 5.4.2 5.4.3 5.4.4 5.4.5 5.4.6 5.5 5.5.1 5.5.2 5.5.3 5.5.4 Companion Diagnostics ........................................................................ 200 Liquid Biopsy ........................................................................................ 209 Other Molecular Diagnostics ................................................................ 213 Medical Imaging.................................................................................. 216 Imaging Analytics ................................................................................. 220 Imaging Computer-Aided Detection (CADx) ......................................... 221 Digital Health and Information Technology ................................................ 222 Clinical Decision Support Systems (CDSS) ..................................... 227 Big Data Analytics .............................................................................. 228 IT Infrastructure .................................................................................. 232 Genomics Informatics ........................................................................ 234 In-Silico Informatics ........................................................................... 237 Mobile Health ...................................................................................... 238 Precision Therapeutics ................................................................................. 241 Clinical Trials ...................................................................................... 242 Cell Therapy ........................................................................................ 244 Drug Discovery and Research .......................................................... 247 Gene Therapy ..................................................................................... 250 6. Global Precision Medicine Market (by Application) ........................................ 254 6.1 6.2 Overview ........................................................................................................ 254 Oncology ........................................................................................................ 257 6.2.1 Government Initiatives ....................................................................... 259 6.2.2 Key Insights ........................................................................................ 260 6.2.3 Drivers and Challenges ...................................................................... 261 6.2.4 Cancer Precision Medicine Drugs and Indications ......................... 261 6.2.5 Recent Key Developments ................................................................ 263 6.3 Infectious Diseases ....................................................................................... 264 6.3.1 Infectious Diseases Precision Medicine Drugs and Indications .... 267 6.4 Neurology/Physiatry ..................................................................................... 267 6.4.1 Neurology Precision Medicine Drugs and Indications .................... 269 6.5 Cardiovascular .............................................................................................. 270 6.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications .......................................................................................... 272 All rights reserved at BIS Research 10

  11. Global Precision Medicine Market 6.6 Lifestyle and Endocrinology ........................................................................ 272 6.6.1 Endocrinology Precision Medicine Drugs and Indications ............ 274 6.7 Gastroenterology .......................................................................................... 274 6.7.1 Gastroenterology Precision Medicine Drugs and Indications ........ 275 6.8 Other Applications ........................................................................................ 276 6.8.1 Precision Drugs for Other Applications ........................................... 277 7. Global Precision Medicine Market (by Region) ................................................ 280 7.1 7.2 Overview ........................................................................................................ 280 North America ............................................................................................... 282 7.2.1 North America Precision Medicine Market Dynamics ..................... 283 7.2.2 The U.S. ............................................................................................... 286 7.2.2.1 Market Statistics ................................................................................... 286 7.2.2.2 Overview of Precision Medicine ........................................................... 287 7.2.2.3 Key Trends ........................................................................................... 287 7.2.2.4 Promoting Factors ................................................................................ 288 7.2.2.5 Recent Key Developments ................................................................... 288 7.2.2.6 Funding Scenario/Investments ............................................................. 289 7.2.2.7 Regulatory Scenario ............................................................................. 289 7.2.2.8 Key Players .......................................................................................... 290 7.2.3 Canada ................................................................................................ 290 7.2.3.1 Market Statistics ................................................................................... 290 7.2.3.2 Overview of Precision Medicine ........................................................... 291 7.2.3.3 Key Trends ........................................................................................... 292 7.2.3.4 Promoting Factors ................................................................................ 292 7.2.3.5 Recent Key Developments ................................................................... 292 7.2.3.6 Funding Scenario ................................................................................. 293 7.2.3.7 Regulatory Scenario ............................................................................. 293 7.2.3.8 Key Players .......................................................................................... 293 7.3 Europe ............................................................................................................ 294 7.3.1 Europe Precision Medicine Market Dynamics ................................. 295 7.3.2 Germany .............................................................................................. 298 7.3.2.1 Market Statistics ................................................................................... 298 7.3.2.2 Overview of Precision Medicine ........................................................... 299 All rights reserved at BIS Research 11

  12. Global Precision Medicine Market 7.3.2.3 7.3.2.4 7.3.2.5 7.3.2.5.1 7.3.3 7.3.3.1 7.3.3.2 7.3.3.3 7.3.3.4 7.3.3.5 7.3.3.6 7.3.4 7.3.4.1 7.3.4.2 7.3.4.3 7.3.4.4 7.3.4.5 7.3.4.6 7.3.5 7.3.5.1 7.3.5.2 7.3.5.3 7.3.5.4 7.3.5.5 7.3.5.6 7.3.5.7 7.3.6 7.3.6.1 7.3.6.2 7.3.6.3 7.3.6.4 7.3.6.5 7.3.6.6 Key Trends ........................................................................................... 300 Promoting Factors ................................................................................ 300 Recent Key Developments ................................................................... 300 Key Players ..................................................................................... 301 France .................................................................................................. 301 Market Statistics ................................................................................... 301 Overview of Precision Medicine ........................................................... 302 Key Trends ........................................................................................... 303 Promoting Factors ................................................................................ 303 Recent Key Developments ................................................................... 303 Key Players .......................................................................................... 304 Italy ...................................................................................................... 304 Market Statistics ................................................................................... 304 Overview of Precision Medicine ........................................................... 305 Key Trends ........................................................................................... 306 Promoting Factors ................................................................................ 306 Recent Key Developments ................................................................... 306 Funding Scenario/Investments ............................................................. 306 The U.K. ............................................................................................... 307 Market Statistics ................................................................................... 307 Overview of Precision Medicine ........................................................... 308 Key Trends ........................................................................................... 309 Promoting Factors ................................................................................ 309 Recent Key Developments ................................................................... 309 Funding Scenario/Investments ............................................................. 309 Key Players .......................................................................................... 310 Spain .................................................................................................... 310 Market Statistics ................................................................................... 310 Overview of Precision Medicine ........................................................... 311 Key Trends ........................................................................................... 312 Promoting Factors ................................................................................ 312 Recent Key Developments ................................................................... 312 Key Players .......................................................................................... 313 All rights reserved at BIS Research 12

  13. Global Precision Medicine Market 7.3.7 7.3.7.1 7.3.7.2 7.4 7.4.1 7.4.1.1 7.4.1.2 7.4.1.3 7.4.1.4 7.4.1.5 7.4.1.6 7.4.1.7 7.4.2 7.4.2.1 7.4.2.2 7.4.2.3 7.4.2.4 7.4.2.5 7.4.2.6 7.4.2.7 7.4.3 7.4.3.1 7.4.3.2 7.4.3.3 7.4.3.4 7.4.3.5 7.4.3.6 7.4.3.7 7.4.4 7.4.4.1 7.4.4.2 7.4.4.3 7.4.4.4 Rest-of-Europe.................................................................................... 313 Market Statistics ................................................................................... 313 Switzerland ........................................................................................... 314 Asia-Pacific (APAC) ...................................................................................... 315 Asia-Pacific Precision Medicine Market Dynamics ......................... 317 China .................................................................................................... 320 Market Statistics ................................................................................... 320 Overview of Precision Medicine ........................................................... 321 Key Trends ........................................................................................... 322 Promoting Factors ................................................................................ 322 Recent Key Developments ................................................................... 322 Key Players .......................................................................................... 323 Japan ................................................................................................... 323 Market Statistics ................................................................................... 323 Overview of Precision Medicine ........................................................... 324 Key Trends ........................................................................................... 325 Promoting Factors ................................................................................ 325 Recent Key Developments ................................................................... 325 Reimbursement Scenario ..................................................................... 326 Key Players .......................................................................................... 326 Australia .............................................................................................. 326 Market Statistics ................................................................................... 326 Overview of Precision Medicine ........................................................... 327 Key Trends ........................................................................................... 328 Promoting Factors ................................................................................ 328 Recent Key Developments ................................................................... 328 Regulatory Scenario ............................................................................. 329 Key Players .......................................................................................... 329 India ..................................................................................................... 329 Market Statistics ................................................................................... 329 Overview of Precision Medicine ........................................................... 331 Key Trends ........................................................................................... 331 Promoting Factors ................................................................................ 332 All rights reserved at BIS Research 13

  14. Global Precision Medicine Market 7.4.4.5 7.4.4.6 7.4.5 7.4.5.1 7.4.5.2 7.4.5.2.1 7.4.5.3 7.4.5.4 7.5 7.5.1 7.5.2 7.5.2.1 7.5.2.2 7.5.3 7.5.3.1 7.5.3.2 7.5.3.3 7.5.4 7.5.4.1 7.6 7.6.1 7.6.1.1 7.6.1.2 7.6.1.3 7.6.1.4 7.6.1.5 7.6.1.6 7.6.1.7 Recent Key Developments ................................................................... 332 Key Players .......................................................................................... 333 Rest-of-Asia-Pacific (RoAPAC) ......................................................... 333 Market Statistics ................................................................................... 333 Singapore ............................................................................................. 335 Regulatory Framework .................................................................... 335 South Korea ......................................................................................... 335 Vietnam ................................................................................................ 336 Latin America ................................................................................................ 337 Latin America Precision Medicine Market Dynamics ...................... 339 Brazil .................................................................................................... 341 Market Statistics ................................................................................... 341 Overview of Precision Medicine ........................................................... 342 Mexico ................................................................................................. 343 Market Statistics ................................................................................... 343 Overview of Precision Medicine ........................................................... 344 Recent Key Developments ................................................................... 345 Rest-of-Latin America (RoLA) ........................................................... 345 Market Statistics ................................................................................... 345 Rest-of-the-World (RoW) .............................................................................. 346 Market Statistics ................................................................................. 346 Middle East Precision Market Dynamics .............................................. 348 Africa Precision Medicine Market Dynamics ......................................... 349 Israel ..................................................................................................... 350 Saudi Arabia ......................................................................................... 351 United Arab Emirates ........................................................................... 351 South Africa .......................................................................................... 352 Russia .................................................................................................. 353 8. Company Profile ................................................................................................. 354 8.1 Abbott Laboratories. ..................................................................................... 354 8.1.1 Company Overview ............................................................................ 354 8.1.2 Role of Abbott Laboratories, Inc.in the Global Precision Medicine Market.................................................................................. 354 All rights reserved at BIS Research 14

  15. Global Precision Medicine Market Key Insights about Financial Health of the Company ..................... 358 SWOT Analysis ................................................................................... 359 Almac Group Ltd. .......................................................................................... 360 8.2.1 Company Overview ............................................................................ 360 8.2.2 Role of Almac Group Ltd. in the Global Precision Medicine Market .................................................................................................. 360 8.2.3 SWOT Analysis ................................................................................... 361 8.3 Amgen Inc. ..................................................................................................... 362 8.3.1 Company Overview ............................................................................ 362 8.3.2 Role of Amgen Inc. in the Global Precision Medicine Market ........ 362 8.3.3 Key Insights about Financial Health of the Company ..................... 364 8.3.4 SWOT Analysis ................................................................................... 365 8.4 ANGLE plc ..................................................................................................... 366 8.4.1 Company Overview ............................................................................ 366 8.4.2 Role of ANGLE plc in the Global Precision Medicine Market ......... 366 8.4.3 Key Insights about Financial Health of the Company ..................... 368 8.4.4 SWOT Analysis ................................................................................... 369 8.5 Astellas Pharma Inc. ..................................................................................... 370 8.5.1 Company Overview ............................................................................ 370 8.5.2 Role of Astellas Pharma Inc.in the Global Precision Medicine Market .................................................................................................. 370 8.5.3 Key Insights about Financial Health of the Company ..................... 372 8.5.4 SWOT Analysis ................................................................................... 373 8.6 Astra Zeneca PLC ......................................................................................... 374 8.6.1 Company Overview ............................................................................ 374 8.6.2 Role of Astra Zeneca PLC in the Global Precision Medicine Market .................................................................................................. 374 8.6.3 Key Insights about Financial Health of the Company ..................... 377 8.6.4 SWOT Analysis ................................................................................... 378 8.7 ASURAGEN INC. ........................................................................................... 379 8.7.1 Company Overview ............................................................................ 379 8.7.2 Role of ASURAGEN Inc. in the Global Precision Medicine Market .................................................................................................. 379 8.7.3 SWOT Analysis ................................................................................... 380 8.1.3 8.1.4 8.2 All rights reserved at BIS Research 15

  16. Global Precision Medicine Market 8.8 Bio-Rad Laboratories, Inc. ............................................................................ 381 8.8.1 Company Overview ............................................................................ 381 8.8.2 Role of Bio-Rad Laboratories, Inc.in the Global Precision Medicine Market.................................................................................. 381 8.8.3 Key Insights about Financial Health of the Company ..................... 384 8.8.4 SWOT Analysis ................................................................................... 385 8.9 bioMérieux SA. .............................................................................................. 386 8.9.1 Company Overview ............................................................................ 386 8.9.2 Role of bioMérieux SA. in the Global Precision Medicine Market .................................................................................................. 386 8.9.3 Key Insights about Financial Health of the Company ..................... 389 8.9.4 SWOT Analysis ................................................................................... 390 8.10Bristol-Myers Squibb Company ................................................................... 391 8.10.1 Company Overview ............................................................................ 391 8.10.2 Role of Bristol-Myers Squibb Company in the Global Precision Medicine Market ................................................................ 391 8.10.3 Key Insights about Financial Health of the Company ..................... 393 8.10.4 SWOT Analysis ................................................................................... 394 8.11Canon Inc. ...................................................................................................... 395 8.11.1 Company Overview ............................................................................ 395 8.11.2 Role of Canon Inc. in the Global Precision Medicine Market ......... 395 8.11.3 Key Insights about Financial Health of the Company ..................... 396 8.11.4 SWOT Analysis ................................................................................... 399 8.12CETICS Healthcare Technologies GmbH .................................................... 400 8.12.1 Company Overview ............................................................................ 400 8.12.2 Role CETICS Healthcare Technologies GmbHin the Global Precision Medicine Market ................................................................ 400 8.12.3 Figure SWOT Analysis ....................................................................... 401 8.13Danaher Corporation .................................................................................... 402 8.13.1 Company Overview ............................................................................ 402 8.13.2 Role of Danaher Corporation in the Global Precision Medicine Market .................................................................................................. 402 8.13.3 Key Insights about Financial Health of the Company ..................... 405 8.13.4 SWOT Analysis ................................................................................... 406 All rights reserved at BIS Research 16

  17. Global Precision Medicine Market 8.14Eli Lilly and Company Limited ..................................................................... 407 8.14.1 Company Overview ............................................................................ 407 8.14.2 Role of Eli Lilly and Company Limited in the Global Precision Medicine Market.................................................................................. 407 8.14.3 Key Insights about Financial Health of the Company ..................... 410 8.14.4 SWOT Analysis ................................................................................... 411 8.15Epic Sciences, Inc. ........................................................................................ 412 8.15.1 Company Overview ............................................................................ 412 8.15.2 Role Epic Sciences, Inc. in the Global Precision Medicine Market .................................................................................................. 412 8.15.3 SWOT Analysis ................................................................................... 413 8.16F. Hoffmann-La Roche AG ............................................................................ 414 8.16.1 Company Overview ............................................................................ 414 8.16.2 Role of F.Hoffman-LA Roche AG in the Global Precision Medicine Market.................................................................................. 414 8.16.3 Key Insights about Financial Health of the Company ..................... 417 8.16.4 SWOT Analysis ................................................................................... 418 8.17GE Corporation ............................................................................................. 419 8.17.1 Company Overview ............................................................................ 419 8.17.2 Role of GE Corporation in the Global Precision Medicine Market .................................................................................................. 419 8.17.3 Key Insights about Financial Health of the Company ..................... 422 8.17.4 SWOT Analysis ................................................................................... 423 8.18Gilead Sciences, Inc. .................................................................................... 424 8.18.1 Company Overview ............................................................................ 424 8.18.2 Role of Gilead Sciences, Inc. in the Global Precision Medicine Market .................................................................................................. 424 8.18.3 Key Insights about Financial Health of the Company ..................... 427 8.18.4 SWOT Analysis ................................................................................... 428 8.19GlaxoSmithKline Plc ..................................................................................... 429 8.19.1 Company Overview ............................................................................ 429 8.19.2 Role of GlaxoSmithKline Plc in the Global Precision Medicine Market .................................................................................................. 429 8.19.3 Key Insights about Financial Health of the Company ..................... 432 8.19.4 SWOT Analysis ................................................................................... 433 All rights reserved at BIS Research 17

  18. Global Precision Medicine Market 8.20IBM Corporation ............................................................................................ 434 8.20.1 Company Overview ............................................................................ 434 8.20.2 Role of IBM Corporation in the Global Precision Medicine Market .................................................................................................. 434 8.20.3 Key Insights about Financial Health of the Company ..................... 437 8.20.4 SWOT Analysis ................................................................................... 438 8.21Illumina, Inc. .................................................................................................. 439 8.21.1 Company Overview ............................................................................ 439 8.21.2 Role of Illumina, Inc. in the Global Precision Medicine Market ...... 439 8.21.3 Key Insights about Financial Health of the Company ..................... 442 8.21.4 SWOT Analysis ................................................................................... 443 8.22Intomics A/S .................................................................................................. 444 8.22.1 Company Overview ............................................................................ 444 8.22.2 Role Intomics A/S in the Global Precision Medicine Market .......... 444 8.22.3 SWOT Analysis ................................................................................... 445 8.23Johnson & Johnson ...................................................................................... 446 8.23.1 Company Overview ............................................................................ 446 8.23.2 Role of Johnson and Johnson in the Global Precision Medicine Market.................................................................................. 446 8.23.3 Key Insights about Financial Health of the Company ..................... 449 8.23.4 SWOT Analysis ................................................................................... 450 8.24Konica Minolta, Inc. ...................................................................................... 451 8.24.1 Company Overview ............................................................................ 451 8.24.2 Role of Konica Minolta, Inc. in the Global Precision Medicine Market .................................................................................................. 451 8.24.3 Key Insights about Financial Health of the Company ..................... 452 8.24.4 SWOT Analysis ................................................................................... 455 8.25Laboratory Corporation of America ............................................................ 456 8.25.1 Company Overview ............................................................................ 456 8.25.2 Role of Lab Corporation of America in the Global Precision Medicine Market.................................................................................. 456 8.25.3 Key Insights about Financial Health of the Company ..................... 457 8.25.4 SWOT Analysis ................................................................................... 459 8.26MDx Health, Inc. ............................................................................................ 460 All rights reserved at BIS Research 18

  19. Global Precision Medicine Market Company Overview ............................................................................ 460 Role of MDx Health, Inc. in the Global Precision Medicine Market .................................................................................................. 460 Key Insights about Financial Health of the Company ..................... 462 SWOT Analysis ................................................................................... 463 8.27Menarini Silicon Biosystems, Inc. ............................................................... 464 8.27.1 Company Overview ............................................................................ 464 8.27.2 Role Menarini Silicon Biosystems, Inc. in the Global Precision Medicine Market.................................................................................. 464 8.27.3 SWOT Analysis ................................................................................... 466 8.28Merck & Co., Inc. ........................................................................................... 467 8.28.1 Company Overview ............................................................................ 467 8.28.2 Role of Merck & Co., Inc. in the Global Precision Medicine Market .................................................................................................. 467 8.28.3 Key Insights about Financial Health of the Company ..................... 470 8.28.4 SWOT Analysis ................................................................................... 471 8.29Myriad Genetics, Inc. .................................................................................... 472 8.29.1 Company Overview ............................................................................ 472 8.29.2 Role of Myriad Genetics, Inc. in the Global Precision Medicine Market .................................................................................................. 472 8.29.3 Key Insights about Financial Health of the Company ..................... 475 8.29.4 SWOT Analysis ................................................................................... 476 8.30Novartis AG. .................................................................................................. 477 8.30.1 Company Overview ............................................................................ 477 8.30.2 Role of Novartis AG in the Global Precision Medicine Market ....... 477 8.30.3 Key Insights about Financial Health of the Company ..................... 480 8.30.4 SWOT Analysis ................................................................................... 481 8.31Oracle Corporation. ...................................................................................... 482 8.31.1 Company Overview ............................................................................ 482 8.31.2 Role of Oracle Corporation in the Global Precision Medicine Market .................................................................................................. 482 8.31.3 Key Insights about Financial Health of the Company ..................... 484 8.31.4 SWOT Analysis ................................................................................... 485 8.32Pacific Biosciences of California, Inc. ......................................................... 486 8.26.1 8.26.2 8.26.3 8.26.4 All rights reserved at BIS Research 19

  20. Global Precision Medicine Market Company Overview ............................................................................ 486 Role of Pacific Biosciences of California, Inc. in the Global Precision Medicine Market ............................................................... 486 Key Insights about Financial Health of the Company ..................... 488 SWOT Analysis ................................................................................... 489 8.33Partek, Inc. ..................................................................................................... 490 8.33.1 Company Overview ............................................................................ 490 8.33.2 Role Partek, Inc. in the Global Precision Medicine Market ............. 490 8.33.3 SWOT Analysis ................................................................................... 491 8.34Pfizer, Inc. ...................................................................................................... 492 8.34.1 Company Overview ............................................................................ 492 8.34.2 Role of Pfizer, Inc. in the Global Precision Medicine Market .......... 492 8.34.3 Key Insights about Financial Health of the Company ..................... 495 8.34.4 SWOT Analysis ................................................................................... 496 8.35QIAGEN N.V ................................................................................................... 497 8.35.1 Company Overview ............................................................................ 497 8.35.2 Role of Qiagen N.V in the Global Precision Medicine Market ......... 497 8.35.3 Key Insights about Financial Health of the Company ..................... 501 8.35.4 SWOT Analysis ................................................................................... 502 8.36Quest Diagnostics Inc................................................................................... 503 8.36.1 Company Overview ............................................................................ 503 8.36.2 Role of Quest Diagnostics Inc. in the Global Precision Medicine Market.................................................................................. 503 8.36.3 Key Insights about Financial Health of the Company ..................... 504 8.36.4 SWOT Analysis ................................................................................... 506 8.37Randox Laboratories Ltd. ............................................................................. 507 8.37.1 Company Overview ............................................................................ 507 8.37.2 Role of Randox Laboratories Ltd. in the Global Precision Medicine Market.................................................................................. 507 8.37.3 SWOT Analysis ................................................................................... 508 8.38Sanofi SA ....................................................................................................... 509 8.38.1 Company Overview ............................................................................ 509 8.38.2 Role of Sanofi SA in the Global Precision Medicine Market ........... 509 8.38.3 Key Insights about Financial Health of the Company ..................... 512 8.32.1 8.32.2 8.32.3 8.32.4 All rights reserved at BIS Research 20

  21. Global Precision Medicine Market SWOT Analysis ................................................................................... 513 8.39Sysmex Corporation ..................................................................................... 514 8.39.1 Company Overview ............................................................................ 514 8.39.2 Role of Sysmex Corporation in the Global Precision Medicine Market .................................................................................................. 514 8.39.3 Key Insights about Financial Health of the Company ..................... 516 8.39.4 SWOT Analysis ................................................................................... 517 8.40Teva Pharmaceuticals Industries Ltd. ......................................................... 518 8.40.1 Company Overview ............................................................................ 518 8.40.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Precision Medicine Market ............................................................... 518 8.40.3 Key Insights about Financial Health of the Company ..................... 521 8.40.4 SWOT Analysis ................................................................................... 522 8.41Thermo Fisher Scientific, Inc. ...................................................................... 523 8.41.1 Company Overview ............................................................................ 523 8.41.2 Role of Thermo Fisher Scientific Inc. in the Global Precision Medicine Market.................................................................................. 523 8.41.3 Key Insights about Financial Health of the Company ..................... 526 8.41.4 SWOT Analysis ................................................................................... 527 8.42TrovaGene, Inc. ............................................................................................. 528 8.42.1 Company Overview ............................................................................ 528 8.42.2 Role of TrovaGene, Inc. in the Global Precision Medicine Market .................................................................................................. 528 8.42.3 SWOT Analysis ................................................................................... 530 8.38.4 9. Report Scope and Methodology ........................................................................ 531 9.1 9.2 Scope of the Report ...................................................................................... 531 Research Methodology ................................................................................. 532 9.2.1 Primary Research ............................................................................... 534 9.2.2 Secondary Research .......................................................................... 535 9.2.3 Key Data Points from Primary Resources ........................................ 536 9.2.4 Key Data Points from Secondary Sources ....................................... 536 9.2.5 Data Triangulation .............................................................................. 537 10. List of Annexures ............................................................................................... 541 All rights reserved at BIS Research 21

  22. Global Precision Medicine Market 10.1Recent Key Developments and Strategies.................................................. 541 10.2Product Mapping ........................................................................................... 541 10.3Patent Analysis ............................................................................................. 541 10.4Funding Scenario .......................................................................................... 541 10.5List of Precision Medicine Drugs ................................................................. 541 10.6Patent Landscape and Regulatory Bodies .................................................. 541 10.7Cancer Incidence Datasheet ........................................................................ 541 10.8List of Approved Products ........................................................................... 541 10.9Competitive Mapping .................................................................................... 541 10.10PM Initiatives ................................................................................................. 541 10.11List of Universities ........................................................................................ 541 10.12List of Prominent Center of Excellence (CoE) ............................................ 541 10.13Data on Partnerships by Academics, CoE and Industry............................ 541 10.14Precision Medicine Drugs Pipeline Analysis .............................................. 541 All rights reserved at BIS Research 22

  23. Global Precision Medicine Market List of Tables List of Tables Table 1: Comparison of China and the U.S. Healthcare Statistics ...................................................... 50 Table 1.1: Initiatives and Programs ..................................................................................................... 82 Table 2.1: Impact Analysis ................................................................................................................ 103 Table 2.2: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030) ......... 107 Table 2.3: Cancer Incidence by WHO Region, 2012 (Thousands) ................................................... 109 Table 2.4: Cancer Incidence Type in Thousand, 2012 (WHO) ......................................................... 109 Table 2.5: Policy and Guidance Documents from the U.S. FDA ....................................................... 116 Table 4.1: Pipeline Analysis .............................................................................................................. 150 Table 4.2: Precision Medicine Drugs Pipeline Analysis ..................................................................... 153 Table 5.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling ................ 182 Table 5.2: Key Approved Therapeutics with FDA Mandated Companion Diagnostics Tests ........... 202 Table 5.3: List of FDA Approved Companion Diagnostics ................................................................ 203 Table 5.4: Commercially Available Primary and Secondary Analysis Tools Providers ...................... 237 Table 6.1: Cancer Precision Medicine Drugs and Indications ........................................................... 261 Table 6.2: Recent Key Developments .............................................................................................. 263 Table 6.3: Infectious Diseases Precision Medicine Drugs and Indications ........................................ 267 Table 6.4: Neurology Precision Medicine Drugs and Indications ...................................................... 269 Table 6.5: Cardiovascular Precision Medicine Drugs/Tests/ and Indications .................................... 272 Table 6.6: Endocrinology Precision Medicine Drugs and Indications ................................................ 274 Table 6.7: Gastroenterology Precision Medicine Drugs and Indications ........................................... 275 Table 6.8: Precision Drugs for Other Applications ............................................................................ 277 Table 7.1: Funding scenario in Universities ...................................................................................... 308 All rights reserved at BIS Research 23

  24. Global Precision Medicine Market List of List of Figures Figures Figure 1: Precision Medicine: Treatment Tailored to an Individual’s Genetic Structure ....................... 40 Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care ......................................... 41 Figure 3: Chronic Conditions: Key Statistics: 2017 ............................................................................. 42 Figure 4: Long-Term Growth Drivers .................................................................................................. 43 Figure 5: Impact Analysis .................................................................................................................... 44 Figure 6: Global Precision Medicine Market Snapshot ....................................................................... 45 Figure 7: Dominating Segments of Global Precision Medicine Market, 2017 and 2028 ...................... 46 Figure 8: Global Precision Medicine Market (by Ecosystem), 2017 and 2028 .................................... 46 Figure 9: Global Precision Medicine Market, (by Application), 2017 and 2028 ................................... 47 Figure 10: Global Precision Medicine Market (by Region), 2017 and 2028 ........................................ 49 Figure 11: Notable Areas of Strategic Focus across Influential Countries ........................................... 52 Figure 12: Strategies Incorporated to Expand the Global Reach ........................................................ 54 Figure 13: Precision Medicine Funding for Academic Institutions and Research Organizations ......... 55 Figure 14: A Persuasive Market Entry Strategy for Diagnostics and Pharma & Biotech Companies to Capitalize on Precision Medicine ........................................................................................................ 60 Figure 15: Plausible Market Penetration Strategy to Shape the Future of Healthcare ........................ 62 Figure 16: Go To Market Strategy....................................................................................................... 63 Figure 17: Value Assessment Frameworks ........................................................................................ 66 Figure 18: Product/Service Promotion Strategies ............................................................................... 67 Figure 19: Precision Medicine: A Trigger to Unfold Innovative Business Model .................................. 68 Figure 20: Fixable Gaps in the Field of Precision Medicine ................................................................ 69 Figure 21: Estimated Ratios of Cost per Quality-Adjusted Life Year (QALY) Gained for Precision or Personalized Medicine Tests .............................................................................................................. 71 Figure 22: Impact of Precision Medicine on Researchers, Manufacturers, and Consumers ............... 73 Figure 23: Opportunities and Challenges for Researchers, Providers, and Patients ........................... 74 Figure 1.1: Precision Medicine Approach ........................................................................................... 76 Figure 1.2: Evolution of Precision Medicine Technology ..................................................................... 77 Figure 1.3: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy .............................................................................................................................................. 79 Figure 1.4: Precision Medicine: Remodeling Framework .................................................................... 81 Figure 1.5: Precision Medicine: Enabling Technologies ...................................................................... 87 All rights reserved at BIS Research 24

  25. Global Precision Medicine Market Figure 1.6: Structured Big Data Reporting Benefits ............................................................................ 96 Figure 1.7: Generalized Process for the Microarray .......................................................................... 101 Figure 2.1: Market Dynamics of Global Precision Medicine Market .................................................. 102 Figure 2.2: Total Number of Genetic Products in Market .................................................................. 105 Figure 2.3: Total Number of Genetic Products in Market .................................................................. 106 Figure 2.4: % of Patients Whose Tumors Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs ................................................................................................................ 108 Figure 2.5: Gene Therapy Products in Pipeline ................................................................................ 118 Figure 2.6: Sales Forecast for Gene Therapy Products (Yescarta and Kymriah), $ Million ............... 118 Figure 2.7: Precision Medicine Deals (2010-2017) ........................................................................... 120 Figure 3.1: Competitive Landscape, January 2012-December 2018 ................................................ 121 Figure 3.2: Share of Key Developments and Strategies (January 2012-December 2018) ................ 122 Figure 3.3: Joint Ventures, Partnerships, Agreements, and Collaborations Share by Companies (January 2012-December 2018) ....................................................................................................... 124 Figure 3.4: Product launches, Enhancements, and Upgradation Share by Companies (January 2012- December 2018) ............................................................................................................................... 125 Figure 3.5: Product Approvals Share by Companies (January 2012-December 2018) ..................... 126 Figure 3.6: Merger and Acquisitions Share by Companies (January 2012-December 2018)............ 127 Figure 3.7: Business Expansion Share by Companies (January 2012-December 2018) .................. 128 Figure 3.8: Other Developments Share by Companies (January 2012-December 2018) ................. 129 Figure 3.9: Market Share Analysis by Applied Sciences, 2017 ......................................................... 131 Figure 3.10: Market Share Analysis by Precision Diagnostics, 2017 ................................................ 133 Figure 3.11: Market Share Analysis by Precision Therapeutics, 2017 .............................................. 135 Figure 3.12: Market Share Analysis by Digital Health and IT, 2017 .................................................. 136 Figure 3.13: Porter’s Five Forces Analysis ........................................................................................ 138 Figure 3.14: Definition of Suppliers and Buyers in the Precision Medicine Market ............................ 139 Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2015-2028 .......................................... 140 Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2015-2028 .............................................. 141 Figure 3.17: Threat of New Entrant: Overall Impact, 2015-2028 ....................................................... 142 Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028 ............................................ 143 Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2015-2028 ......................................... 144 Figure 3.20: Supply Chain Analysis: Global Precision Medicine Market ........................................... 145 Figure 4.1: Patent Analysis ............................................................................................................... 147 All rights reserved at BIS Research 25

  26. Global Precision Medicine Market Figure 4.2: Role of FDA in Advancing Precision Medicine ................................................................ 149 Figure 5.1: Precision Medicine: The Ecosystem ............................................................................... 157 Figure 5.2: Global Precision Medicine Market (by Ecosystem) ......................................................... 158 Figure 5.3: Global Precision Medicine Market (by Ecosystem), 2017-2028 ...................................... 159 Figure 5.4: Global Precision Medicine Market (by Applied Sciences) ............................................... 160 Figure 5.5: Global Precision Medicine Market (by Applied Sciences), 2017-2028 ............................ 160 Figure 5.6: Precision Medicine: Omics Sciences .............................................................................. 161 Figure 5.7: Global Precision Medicine Applied Sciences Market (by Type), 2017-2028 ................... 162 Figure 5.8: Precision Medicine: Genomics ........................................................................................ 163 Figure 5.9: Global Precision Medicine Genomics Market, 2017-2028 .............................................. 163 Figure 5.10: Global Precision Medicine Genomics Market (by Technology), 2017-2028 .................. 164 Figure 5.11: Global Precision Medicine PCR Market, 2017-2028 ..................................................... 165 Figure 5.12: Global Precision Medicine PCR Market (by Product Type), 2017-2028 ........................ 166 Figure 5.13: Global Precision Medicine PCR Market (by End User), 2017-2028 .............................. 167 Figure 5.14: Global Precision Medicine PCR Market (by Region), 2017-2028 .................................. 167 Figure 5.15: Evolution of Next-Generation Sequencing .................................................................... 169 Figure 5.16: Global Precision Medicine NGS Market, 2017-2028 ..................................................... 170 Figure 5.17: Global Precision Medicine PM NGS Market (by Product Type), 2017-2028 ................. 171 Figure 5.18: Global Precision Medicine NGS Market (by Technology), 2017-2028 .......................... 172 Figure 5.19: Global Precision Medicine NGS Market (by End User), 2017-2028 .............................. 173 Figure 5.20: Global Precision Medicine NGS Market (by Region), 2017-2028 ................................. 174 Figure 5.21: Global Precision Medicine Genome Editing Market, 2017-2028 ................................... 175 Figure 5.22: Global Precision Medicine Genome Editing Market (by Product Type), 2017-2028 ...... 175 Figure 5.23: Global Precision Medicine Genome Editing Market (by End User), 2017-2028 ............ 176 Figure 5.24: Global Precision Medicine Genome Editing Market (by Region), 2017-2028 ................ 177 Figure 5.25: Global Precision Medicine Other Technologies Market, 2017-2028 ............................. 178 Figure 5.26: Global Precision Medicine Other Technologies Market (by Region), 2017-2028 .......... 179 Figure 5.27: Clinical Applications of Pharmacogenomics Testing ..................................................... 180 Figure 5.28: Role of Biomarkers in Pharmacogenomics ................................................................... 181 Figure 5.29: Role of FDA In Pharmacogenomics .............................................................................. 184 Figure 5.30: Global Precision Medicine Pharmacogenomics Market, 2017-2028 ............................. 185 Figure 5.31: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2017-2028 ........................................................................................................................................ 186 All rights reserved at BIS Research 26

  27. Global Precision Medicine Market Figure 5.32: Global Precision Medicine Pharmacogenomics Market (by End User), 2017-2028 ...... 186 Figure 5.33: Global Precision Medicine Pharmacogenomics Market (by Region), 2017-2028 .......... 187 Figure 5.34: Global Precision Medicine Other Applied Sciences Market, 2017-2028 ....................... 188 Figure 5.35: Precision Medicine: Diagnostics ................................................................................... 189 Figure 5.36: Global Precision Medicine Market (by Precision Diagnostics)....................................... 190 Figure 5.37: Global Precision Medicine Market (by Precision Diagnostics), 2017-2028 ................... 190 Figure 5.38: Global Precision Medicine Diagnostics Market (by Type), 2017-2028 .......................... 191 Figure 5.39: General Workflow of a Molecular Diagnostic Assay ...................................................... 193 Figure 5.40: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics) .................. 193 Figure 5.41: Global Precision Medicine Molecular Diagnostics Market, 2017-2028 .......................... 194 Figure 5.42: Global Precision Medicine Molecular Diagnostics Market (by Type), 2017-2028 .......... 195 Figure 5.43: Benefits and Risks Associated with NIPT ..................................................................... 197 Figure 5.44: Global Precision Medicine NIPT Market, 2017-2028 .................................................... 197 Figure 5.45: Global Precision Medicine NIPT Market (by Platform), 2017-2028 ............................... 198 Figure 5.46: Global Precision Medicine NIPT Market (by Region), 2017-2028 ................................. 199 Figure 5.47: Drug and Companion Diagnostics Development Process ............................................ 201 Figure 5.48: Benefits and Risks Associated with Companion Diagnostics ........................................ 203 Figure 5.49: Global Precision Medicine Companion Diagnostics Market, 2017-2028 ....................... 205 Figure 5.50: Global Precision Medicine Companion Diagnostics Market (by Technology), 2017-2028 .......................................................................................................................................................... 206 Figure 5.51: Global Precision Medicine Companion Diagnostics Market (by Indication), 2017-2028 207 Figure 5.52: Global Precision Medicine Companion Diagnostics Market (by Region), 2017-2028 ... 208 Figure 5.53: Clinical Applications of Liquid Biopsy ............................................................................ 209 Figure 5.54: Global Precision Medicine Liquid Biopsy Market, 2017-2028 ....................................... 210 Figure 5.55: Global Precision Medicine Liquid Biopsy Market (by Indication), 2017-2028 ................ 211 Figure 5.56: Global Precision Medicine Liquid Biopsy Market (by Region), 2017-2028 .................... 211 Figure 5.57: Global Precision Medicine Other Molecular Diagnostics Market, 2017-2028 ................ 213 Figure 5.58: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2017-2028 .......................................................................................................................................................... 214 Figure 5.59: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2017-2028 .......................................................................................................................................................... 215 Figure 5.60: Global Precision Medicine Medical Imaging Market, 2017-2028 ................................... 217 Figure 5.61: Global Precision Medicine Medical Imaging Market (by Type), 2017-2028 ................... 218 All rights reserved at BIS Research 27

  28. Global Precision Medicine Market Figure 5.62: Global Precision Medicine Medical Imaging Market (by Region), 2017-2028 ............... 219 Figure 5.63: Global Precision Medicine Imaging Analytics Market, 2017-2028 ................................. 220 Figure 5.64: Global Precision Medicine CADx Market, 2017-2028 ................................................... 221 Figure 5.65: Global Precision Medicine Digital Health and Information Technology Market, 2017-2028 .......................................................................................................................................................... 223 Figure 5.66: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2017-2028 ........................................................................................................................................ 224 Figure 5.67: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2017-2028 .............................................................................................................................. 225 Figure 5.68: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2017-2028 ........................................................................................................................................ 226 Figure 5.69: Global Precision Medicine CDSS Market, 2017-2028 ................................................... 227 Figure 5.70: Big Data Attributes ........................................................................................................ 229 Figure 5.71: Global Precision Medicine Big Data Analytics Market, 2017-2028 ................................ 230 Figure 5.72: Big Data Analytics: Key Benefits ................................................................................... 231 Figure 5.73: Global Precision Medicine IT Infrastructure Market, 2017-2028.................................... 232 Figure 5.74: Global Precision Medicine IT Infrastructure Market (by Type), 2017-2028.................... 233 Figure 5.75: Global Precision Medicine Genomics Informatics Market, 2017-2028 .......................... 234 Figure 5.76: Global Precision Medicine Genomics Informatics Market (by Product Type), 2017-2028 .......................................................................................................................................................... 236 Figure 5.77: Global Precision Medicine In-Silico Informatics Market, 2017-2028 .............................. 237 Figure 5.78: Global Precision Medicine Mobile Health Market, 2017-2028 ....................................... 239 Figure 5.79: Global Precision Medicine Therapeutics Market, 2017-2028 ........................................ 241 Figure 5.80: Global Precision Medicine Therapeutics Market (by Type), 2017-2028 ........................ 242 Figure 5.81: Global Precision Medicine Clinical Trials Market, 2017-2028........................................ 243 Figure 5.82: Global Precision Medicine Clinical Trials Market (by Region), 2017-2028 .................... 243 Figure 5.83: Types of Cell Therapy ................................................................................................... 245 Figure 5.84: Global Precision Medicine Cell Therapy Market, 2017-2028 ........................................ 245 Figure 5.85: Global Precision Medicine Cell Therapy Market (by Region), 2017-2028 ..................... 246 Figure 5.86: Global Precision Medicine Drug Discovery and Research Market, 2017-2028 ............. 248 Figure 5.87: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028 .......................................................................................................................................................... 249 Figure 5.88: Types of Gene Therapy ................................................................................................ 250 All rights reserved at BIS Research 28

  29. Global Precision Medicine Market Figure 5.89: Types of Gene Therapy ................................................................................................ 251 Figure 5.90: Global Precision Medicine Gene Therapy Market, 2017-2028 ...................................... 251 Figure 5.91: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028 .......................................................................................................................................................... 252 Figure 6.1: Therapeutic Areas in Precision Medicine ........................................................................ 255 Figure 6.2: Global Precision Medicine Applications Market, 2017-2028 ........................................... 256 Figure 6.3: Types of Cancer ............................................................................................................. 257 Figure 6.4: Global Precision Medicine Oncology Market, 2017-2028 ............................................... 258 Figure 6.5: Global Precision Medicine Infectious Diseases Market, 2017-2028 ................................ 265 Figure 6.6: Number of Deaths by Top 18 Infectious Diseases, 2015 ................................................ 266 Figure 6.7: Global Precision Medicine Neurology/Physiatry Market, 2017-2028 ............................... 268 Figure 6.8: Global Precision Medicine Cardiovascular Market, 2017-2028 ....................................... 271 Figure 6.9: Global Precision Medicine Lifestyle and Endocrinology Market, 2017-2028 ................... 273 Figure 6.10: Global Precision Medicine Gastroenterology Market, 2017-2028 ................................. 275 Figure 6.11: Global Precision Medicine Other Applications Market, 2017-2028................................ 277 Figure 7.1: Global Precision Medicine Market (by Region) ............................................................... 280 Figure 7.2: Global Precision Medicine Market (by Region), 2017 and 2028 ..................................... 281 Figure 7.3: Global Precision Medicine Market (by Region), 2017-2028 ............................................ 281 Figure 7.4: North America Precision Medicine Market, 2017-2028 ................................................... 282 Figure 7.5: North America Precision Medicine Market (by Country), 2017-2028............................... 284 Figure 7.6: North America Precision Medicine Market (by Ecosystem), 2017-2028.......................... 285 Figure 7.7: The U.S. Precision Medicine Market, 2017-2028 ............................................................ 286 Figure 7.8: Canada Precision Medicine Market, 2017-2028 ............................................................. 291 Figure 7.9: Europe Precision Medicine Market, 2017-2028 .............................................................. 294 Figure 7.10: Europe Precision Medicine Market (by Country), 2017-2028 ........................................ 296 Figure 7.11: Europe Precision Medicine Market (by Ecosystem), 2017-2028 ................................... 297 Figure 7.12: Germany Precision Medicine Market, 2017-2028 ......................................................... 298 Figure 7.13: France Precision Medicine Market, 2017-2028 ............................................................. 301 Figure 7.14: Italy Precision Medicine Market, 2017-2028 ................................................................. 304 Figure 7.15: The U.K. Precision Medicine Market, 2017-2028 .......................................................... 307 Figure 7.16: Spain Precision Medicine Market, 2017-2028 ............................................................... 310 Figure 7.17: Rest-of-Europe Precision Medicine Market, 2017-2028 ................................................ 313 Figure 7.18: Asia-Pacific Precision Medicine Market, 2017-2028 ..................................................... 316 All rights reserved at BIS Research 29

  30. Global Precision Medicine Market Figure 7.19: Asia-Pacific Precision Medicine Market (by Country), 2017-2028 ................................. 318 Figure 7.20: Asia-Pacific Precision Medicine Market (by Ecosystem), 2017-2028 ............................ 319 Figure 7.21: China Precision Medicine Market, 2017-2028............................................................... 320 Figure 7.22: Japan Precision Medicine Market, 2017-2028 .............................................................. 323 Figure 7.23: Australia Precision Medicine Market, 2017-2028 .......................................................... 327 Figure 7.24: India Precision Medicine Market, 2017-2028 ................................................................ 330 Figure 7.25: Rest-of- Asia-Pacific Precision Medicine Market, 2017-2028 ........................................ 334 Figure 7.26: Latin America Precision Medicine Market, 2017-2028 .................................................. 338 Figure 7.27: Latin America Precision Medicine Market (by Country), 2017-2028 .............................. 339 Figure 7.28: Latin America Precision Medicine Market (by Ecosystem), 2017-2028 ......................... 340 Figure 7.29: Brazil Precision Medicine Market, 2017-2028 ............................................................... 341 Figure 7.30: Mexico Precision Medicine Market, 2017-2028............................................................. 344 Figure 7.31: Rest-of-Latin America Precision Medicine Market, 2017-2028 ..................................... 345 Figure 7.32: Rest-of-the-World Precision Medicine Market, 2017-2028 ............................................ 347 Figure 7.33: Major Countries in the Middle East Precision Medicine Market..................................... 349 Figure 8.1: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017 .............................................. 355 Figure 8.2: Abbott Laboratories: Revenue (by Business Segment), 2015-2017 ............................... 356 Figure 8.3: Abbott Laboratories: Revenue (by Region), 2015-2017 .................................................. 357 Figure 8.4: Abbott Laboratories R&D Expenditure, 2015-2017 ......................................................... 358 Figure 8.5: Amgen Inc.: Overall Financials, 2015-2017 .................................................................... 363 Figure 8.6: Amgen Inc.: Revenue (by Region), 2015-2017 ............................................................... 364 Figure 8.7: Amgen Inc. R&D Expenditure, 2014-2017 ...................................................................... 364 Figure 8.8: ANGLE plc: Overall Financials, 2015-2017 ..................................................................... 367 Figure 8.9: ANGLE plc: Revenue (by Region), 2015-2017 ............................................................... 368 Figure 8.10: ANGLE plc R&D Expenditure, 2014-2017 .................................................................... 368 Figure 8.11: Astellas Pharma Inc.: Overall Financials, 2015-2017 .................................................... 371 Figure 8.12: Astellas Pharma Inc.: Revenue (by Region), 2015-2017 .............................................. 372 Figure 8.13: Astellas Pharma Inc. R&D Expenditure, 2015-2017 ..................................................... 372 Figure 8.14: Astra Zeneca PLC : Overall Financials, 2015-2017 ...................................................... 375 Figure 8.15: Astra Zeneca PLC: Revenue (by Business Segment), 2015-2017 ............................... 376 Figure 8.16: Astra Zeneca PLC: Revenue (by Region), 2015-2017 .................................................. 376 Figure 8.17: Astra Zeneca PLC R&D Expenditure, 2014-2017 ......................................................... 377 Figure 8.18: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017 ............................................ 382 All rights reserved at BIS Research 30

  31. Global Precision Medicine Market Figure 8.19: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2015-2017 .................... 383 Figure 8.20: Bio-Rad Laboratories, Inc: Revenue (by Region), 2015-2017 ....................................... 383 Figure 8.21: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017 ............................................. 384 Figure 8.22: bioMérieux SA.: Overall Financials, 2015-2017 ............................................................ 387 Figure 8.23: bioMérieux SA.: Revenue (by Business Segment), 2015-2017 .................................... 388 Figure 8.24: bioMérieux SA.: Revenue (by Region), 2015-2017 ....................................................... 388 Figure 8.25: bioMérieux SA. R&D Expenditure, 2014-2017 .............................................................. 389 Figure 8.26: Bristol-Myers Squibb Company: Overall Financials, 2015-2017 ................................... 392 Figure 8.27: Bristol-Myers Squibb Company: Revenue (by Region), 2015-2017 .............................. 393 Figure 8.28: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017 ..................................... 393 Figure 8.29: Canon Inc.: Overall Financials, 2015-2017 ................................................................... 396 Figure 8.30: Canon Inc.: Revenue (by Segment), 2015-2017 ........................................................... 396 Figure 8.31: Canon Inc.: Revenue (by Region), 2015-2017 .............................................................. 397 Figure 8.32: Canon Inc.: R&D Expenditure, 2015-2017 .................................................................... 398 Figure 8.33: Danaher Corporation: Overall Financials, 2015-2017 ................................................... 403 Figure 8.34: Danaher Corporation: Revenue (by Business Segment), 2015-2017 ........................... 403 Figure 8.35: Danaher Corporation: Revenue (by Region), 2015-2017 .............................................. 404 Figure 8.36: Danaher Corporation R&D Expenditure, 2014-2017 ..................................................... 405 Figure 8.37: Eli Lilly and Company Limited: Overall Financials, 2015-2017 ...................................... 408 Figure 8.38: Eli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017 .............. 409 Figure 8.39: Eli Lilly and Company Limited: Revenue (by Region), 2015-2017 ................................ 410 Figure 8.40: Eli Lilly and Company Limited R&D Expenditure, 2014-2017 ....................................... 410 Figure 8.41: F.Hoffman-LA Roche AG: Overall Financials, 2015-2017 ............................................. 415 Figure 8.42: Elli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017 ............. 416 Figure 8.43: F.Hoffman-LA Roche AG : Revenue (by Region), 2015-2017 ..................................... 417 Figure 8.44: F.Hoffman-LA Roche AG R&D Expenditure, 2014-2017 ............................................. 417 Figure 8.45: GE Corporation Limited: Overall Financials, 2015-2017 ............................................... 420 Figure 8.46: GE Corporation: Revenue (by Business Segment), 2015-2017 .................................... 421 Figure 8.47: GE Corporation: Revenue (by Region), 2015-2017 ...................................................... 422 Figure 8.48: GE Corporation R&D Expenditure, 2014-2017 ............................................................. 422 Figure 8.49: Gilead Sciences, Inc.: Overall Financials, 2015-2017 ................................................... 425 Figure 8.50: Gilead Sciences, Inc.: Revenue (by Business Segment), 2015-2017 ........................... 426 Figure 8.51: Gilead Sciences, Inc.: Revenue (by Region), 2015-2017.............................................. 426 All rights reserved at BIS Research 31

  32. Global Precision Medicine Market Figure 8.52: Gilead Sciences, Inc. R&D Expenditure, 2014-2017 .................................................... 427 Figure 8.53: GlaxoSmithKline Plc: Overall Financials, 2015-2017 .................................................... 430 Figure 8.54: GlaxoSmithKline Plc: Revenue (by Business Segment), 2015-2017 ............................ 431 Figure 8.55: GlaxoSmithKline Plc: Revenue (by Region), 2015-2017 ............................................... 431 Figure 8.56: GlaxoSmithKline Plc R&D Expenditure, 2014-2017 ...................................................... 432 Figure 8.57: IBM Corporation: Overall Financials, 2015-2017 .......................................................... 435 Figure 8.58: IBM Corporation: Revenue (by Business Segment), 2015-2017 ................................... 436 Figure 8.59: IBM Corporation: Revenue (by Region), 2015-2017 ..................................................... 437 Figure 8.60: IBM Corporation R&D Expenditure, 2014-2017 ............................................................ 437 Figure 8.61: Illumina, Inc.: Overall Financials, 2015-2017 ................................................................ 440 Figure 8.62: Illumina, Inc.: Revenue (by Business Segment), 2015-2017 ......................................... 441 Figure 8.63: Illumina, Inc.: Revenue (by Region), 2015-2017 ........................................................... 441 Figure 8.64: Illumina, Inc. R&D Expenditure, 2014-2017 .................................................................. 442 Figure 8.65: Johnson and Johnson: Overall Financials, 2015-2017 ................................................. 447 Figure 8.66: Johnson and Johnson: Revenue (by Business Segment), 2015-2017.......................... 448 Figure 8.67: Johnson and Johnson Revenue (by Region), 2015-2017 ............................................. 449 Figure 8.68: Johnson and Johnson R&D Expenditure, 2014-2017 ................................................... 449 Figure 8.69: Konica Minolta, Inc.: Overall Financials, 2015-2017 ..................................................... 452 Figure 8.70: Konica Minolta, Inc.: Revenue (by Segment), 2015-2017 ............................................. 452 Figure 8.71: Konica Minolta, Inc.: Revenue (by Region), 2015-2017 ................................................ 453 Figure 8.72: Konica Minolta, Inc.: R&D Expenditure, 2015-2017 ...................................................... 454 Figure 8.73: Lab Corporation of America: Overall Financials, 2015-2017 ......................................... 457 Figure 8.74: Lab Corporation of America: Revenue (by Business Segment), 2015-2017 ................. 458 Figure 8.75: Lab Corporation of America: Revenue (by Region), 2015-2017 ................................... 458 Figure 8.76: MDx Health, Inc.: Overall Financials, 2015-2017 .......................................................... 461 Figure 8.77: MDx Health, Inc. R&D Expenditure, 2014-2017 ............................................................ 462 Figure 8.78: Merck & Co., Inc.: Overall Financials, 2015-2017 ......................................................... 468 Figure 8.79: Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017 ................................. 469 Figure 8.80: Merck & Co., Inc.: Revenue (by Region), 2015-2017 .................................................... 469 Figure 8.81: Merck & Co., Inc. R&D Expenditure, 2015-2017 .......................................................... 470 Figure 8.82: Myriad Genetics, Inc.: Overall Financials, 2015-2017 ................................................... 473 Figure 8.83: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017 ........................... 474 Figure 8.84: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017 .............................................. 475 All rights reserved at BIS Research 32

  33. Global Precision Medicine Market Figure 8.85: Myriad Genetics, Inc. R&D Expenditure, 2015-2017 ..................................................... 475 Figure 8.86: Novartis AG: Overall Financials, 2015-2017 ................................................................. 478 Figure 8.87: Novartis AG: Revenue (by Business Segment), 2015-2017 ......................................... 479 Figure 8.88: Novartis AG: Revenue (by Region), 2015-2017 ............................................................ 480 Figure 8.89: Novartis AG R&D Expenditure, 2015-2017 ................................................................... 480 Figure 8.90: Oracle Corporation: Overall Financials, 2015-2017 ...................................................... 483 Figure 8.91: Oracle Corporation: Revenue (by Region), 2015-2017 ................................................. 484 Figure 8.92 Oracle Corporation R&D Expenditure, 2015-2017 ......................................................... 484 Figure 8.93: Pacific Biosciences of California, Inc.: Overall Financials, 2015-2017 .......................... 487 Figure 8.94: Pacific Biosciences of California, Inc.: Revenue (by Region), 2015-2017 ..................... 488 Figure 8.95: Pacific Biosciences of California, Inc. R&D Expenditure, 2015-2017 ............................ 488 Figure 8.96: Pfizer, Inc.: Overall Financials, 2015-2017 .................................................................... 493 Figure 8.97: Pfizer, Inc.: Revenue (by Business Segment), 2015-2017 ............................................ 494 Figure 8.98: Pfizer, Inc.: Revenue (by Region), 2015-2017 .............................................................. 495 Figure 8.99: Pfizer, Inc. R&D Expenditure, 2015-2017 ..................................................................... 495 Figure 8.100: Qiagen N.V: Overall Financials, 2015-2017 ................................................................ 498 Figure 8.101: Qiagen N.V: Revenue (by Business Segment), 2015-2017 ........................................ 499 Figure 8.102: Qiagen N.V: Revenue (by Region), 2015-2017 .......................................................... 500 Figure 8.103: Qiagen N.V R&D Expenditure, 2015-2017 .................................................................. 501 Figure 8.104: Quest Diagnostics Inc.: Overall Financials, 2015-2017 ............................................... 504 Figure 8.105: Quest Diagnostics Inc.: Revenue (by Business Segment), 2015-2017 ....................... 505 Figure 8.106: Quest Diagnostics Inc.: Revenue (by Region), 2015-2017 ......................................... 505 Figure 8.107: Sanofi SA: Overall Financials, 2015-2017................................................................... 510 Figure 8.108: Sanofi SA: Revenue (by Business Segment), 2015-2017 ........................................... 511 Figure 8.109: Sanofi SA: Revenue (by Region), 2015-2017 ............................................................. 512 Figure 8.110 Sanofi SA R&D Expenditure, 2015-2017 ..................................................................... 512 Figure 8.111: Sysmex Corporation: Overall Financials, 2015-2017 .................................................. 515 Figure 8.112: Sysmex Corporation: Revenue (by Business Segment), 2015-2017 .......................... 516 Figure 8.113: Sysmex Corporation R&D Expenditure, 2015-2017 .................................................... 516 Figure 8.114: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2015-2017 ........................ 519 Figure 8.115: Teva Pharmaceuticals Industries Ltd.: Revenue (by Business Segment), 2015-2017 519 Figure 8.116: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2015-2017 .................. 520 Figure 8.117: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2015-2017 ......................... 521 All rights reserved at BIS Research 33

  34. Global Precision Medicine Market Figure 8.118: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017 ..................................... 524 Figure 8.119: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017 ............. 525 Figure 8.120: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017 ................................ 526 Figure 8.121 Thermo Fisher Scientific Inc. R&D Expenditure, 2015-2017 ........................................ 526 Figure 8.122: TrovaGene,Inc.: Overall Financials, 2015-2017 .......................................................... 529 Figure 9.1: Global Precision Medicine Market Segmentation ............................................................ 532 Figure 9.2: Figure Scope .................................................................................................................. 533 Figure 9.3: Key data points from primary resources ......................................................................... 536 Figure 9.4: Key data points from secondary resources ..................................................................... 536 Figure 9.5: Top-down Approach (Segment-wise Analysis) ............................................................... 538 Figure 9.6: Bottom-Up Approach (Segmental Analysis) .................................................................... 538 Figure 9.7: Research Methodology Snapshot ................................................................................... 539 Figure 9.8: Assumptions and Limitations .......................................................................................... 540 Figure 9.9: Considered Factors for Data Prediction and Modelling ................................................... 540 All rights reserved at BIS Research 34

  35. Global Precision Medicine Market List of List of A Acronyms cronyms Acronym Description AACR American Association for Cancer Research ACMG American College of Medical Genetics and Genomics ACOG American Congress of Obstrecians and Gynaecologists ACRF Australian Cancer Research Foundation ADRs Adverse Drug Reactions AG Authorized Generic AIIMS All India institute of Medical Sciences ALK Anaplastic Lymphoma Kinase ALS Amyotrophic Lateral Sclerosis AMA American Medical Association AMD Advanced Molecular Detection ANSI American National Standards Institute APAC Asia Pacific APL Acute Promyelocytic Leukemia AVIESAN The French National Alliance for Life Sciences and Health BBRB Bio-repositories and Bio-specimen Research Branch BGI Beijing Genomics Institute BIPMed Brazilian Enterprise on Precision Medicine BLA Biologics License Application BSC Barcelona Supercomputing Center CAP College of American Pathologists All rights reserved at BIS Research 35

  36. Global Precision Medicine Market CAR Chimeric antigen Receptor CATCH Center for Assessment Technology and Continuous Health CCR Center for Cancer Research CDC Center for Disease Control CDP Cancer Diagnosis Program CEPM Centre of Excellence for Precision Medicine CFDA China Food and Drug Administration cfDNA Cell-Free DNA CGH Center for Global Health CIHI Canadian Institute for Health Information CIHR Canadian Institutes of Health Research CIP Cancer Imaging Program CLIA Clinical Laboratory Improvement Amendments CLL Chronic Lymphocytic Leukemia CLP Clinical Laboratory Partners CMI Caris Molecular Intelligence CML Chronic Myeloid Leukemia CMS Centers for Medicare & Medicaid Services CNS Central Nervous System COPD chronic obstructive pulmonary disease CPRD Clinical Practice Research Datalink CRO's Contract Research Organizations CTEP Cancer Therapy Evaluation Program All rights reserved at BIS Research 36

  37. Global Precision Medicine Market CTGA Catalogue of Transmission Genetics in Arabs CTI Centers for Therapeutic Innovation CVD Cardiovascular Disease DBTB Diagnostic Biomarkers and Technology Branch DCTD Operates under NCI Division of Cancer Treatment and Diagnosis DEA Drug Enforcement Agency DEB Diagnostics Evaluation Branch DJSI Dow Jones Sustainability Index DLBCL Diffuse large B-cell lymphoma DOS Denial of Service EBMG European Board of Medical Genetics EDMA European Diagnostics Manufacturers Association EFPIA European Federation of Pharmaceutical Industries and Associations EGFR epidermal growth factor receptor EHRs Electronic Health Record EMA European Medicines Agency eMERGE Electronic Medical Records and Genomics EPFL Ecole Polytechnique Federale De Lausanne EDRN Early Detection Research Network EU European Union Commission FCC Federal communications commission FDA Food Drug and Administration FFPE Formalin Fixed Paraffin Embedded All rights reserved at BIS Research 37

  38. Global Precision Medicine Market FNSSI Forensic & National Security Sciences Institute FY Financial Year GEPs Gene Expression Profiles GINA Genetic Information Non-discrimination Act GIP Global Innovative Pharmaceutical GMTA Global Medical Technology Alliance GNC German National Cohort GSK GlaxoSmithKline GWAS Genome-Wide Association Study HCI Hydrochloride HIMSS Healthcare Information and Management Systems Society HIPAA Health Insurance Portability and Accountability Act HRM High Resolution Melting IBM International Business Machines Corporation ICES Institute for Clinical Evaluative Sciences IDEA Individuals with Disabilities Education Act IFHGS International Federation of Human Genetics Societies IGA International Genetic Alliance IGIB Institute of Genomics and Integrative Biology IMDRF International Medical Device Regulators Forum IMI Innovative Medicines Initiative I-O Immuno-Oncology IVD In -vitro diagnostics All rights reserved at BIS Research 38

  39. Global Precision Medicine Market J&J Johnson & Johnson JAK 2 Januskinase 2 JATE Japan approvals Institute for Telecommunications Equipment JMF Jeffrey Modell Foundation MCSSL Molecular and Cellular Screening of Screen-Detected Lesions mhealth Mobile Health MHLW Ministry of Health, Labor and Welfare MHRA Medicines and Healthcare products Regulatory Agency MRI Magnetic Resonance Imaging NGS Next-Generation Sequencing NHL B-cell non-Hodgkin lymphoma NHLBI National Heart, Lung and Blood Institute NHRIS National Heart Research Institute Singapore NIBSC National Institute for Biological Standards and Control NICE National Institute for Health and Care Excellence NIH National Institute of Health NIHR National Institute for Health Research NIMHANS National Institute of Mental Health and neurosciences NIPT Non-Invasive Prenatal Testing NSCLC Non-Small Cell Lung Cancer OCA Oncomine Comprehensive Assay OECI Organization of European Cancer Institute OICR Ontario Institute for Cancer Research All rights reserved at BIS Research 39

  40. Global Precision Medicine Market Omics Genomics, Proteomics, and Transcriptomics ONCHIT Office of the National Coordinator for Health Information Technology OPHG Office of the Public Health Genomics OSTP Office of Science and Technology Policy RoW Rest of the World SAS Statistical Analysis System SHGP Saudi Human Genome Program SNPs Single Nucleotide Polymorphism SOPs Standard Operating Procedures SPOR Strategy for Patient-Oriented Research STR Short Tandem Repeat All rights reserved at BIS Research 40

  41. Global Precision Medicine Market BIS Research BIS Research Offerings: Offerings: We’re on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. With a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist with market intelligence in the area of emerging technologies, advisory, and other innovative solutions. SYNDICATED REPORTS SYNDICATED REPORTS CUSTOM CUSTOM REPORTS REPORTS BIS Research’s syndicated offerings are curated to assist our readers in getting a firm grip on the forces shaping their industry as well as devising future strategies for sustained innovation processes, and technology planning. In order to help clients keep pace with the dynamic environment of industry, BIS Research provides customized reports, tailored to explore market opportunities unique businesses. growth, to their BIS provide its clients with valuable and actionable information and a multi-angle approach to data intelligence that allows them to access in-depth analyses for the markets. The comprehensive research helps clients in identifying new growth opportunities, revenue pockets and devise go-to-market strategies. Research’s custom offerings Each research report incorporates detailed analysis quantification of - market dynamics, market drivers opportunities, threats, market shares, current and emerging industry trends as well as detailed competitive landscape and intelligence. and subsequent and restraints, Know More Know More Annual Subscriptions: Annual Subscriptions: Quite often, we have clients that have ongoing business intelligence needs and require adequate market data and forecasts across a wide range of emerging technology sectors on a frequent basis. Annual market research subscriptions from BIS Research are ideal for the ongoing requirements (for quality market data and forecasts), of corporates, universities or colleges, and research institutions. Know More All rights reserved at BIS Research 41

  42. Global Precision Medicine Market Disclaimer Disclaimer BIS Research provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed only for the customer's internal use and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the expressed written consent of BIS Research. The customer will neither disclose the contents of the report, whether directly in any media or indirectly through the incorporation in a database, marketing list, report or otherwise; use or permit the use of information to generate any statistical or other information that is or will be provided to third parties; nor voluntarily produce the information in any legal proceedings. Market reports are based on the expectations, estimates, and projections, as of the date such information is available at. Recommendations, if any, contained in this report may or may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, are inherently subject to market fluctuations as well as business, economic, and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 All rights reserved at BIS Research 42

  43. Global Precision Medicine Market BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: info@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com All rights reserved at BIS Research 43

More Related